Home › NDC Lookup › Ingredients › Isotretinoin › 55111-0113-78
Zenatane Isotretinoin 30 mg Capsule, Gelatin Coated — NDC 55111-0113-78 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

NDC 55111-0113-78: Zenatane Isotretinoin 30 mg Capsule, Gelatin Coated

by Dr. Reddy's Laboratories Limited · 10 BLISTER PACK in 1 CARTON / 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK
Inner NDC 55111-113-79 on each blister pack (10 capsule, gelatin coated) inside this package 11-digit 55111-0113-79

This is a package of Zenatane Isotretinoin 30 mg Capsule, Gelatin Coated from Dr. Reddy's Laboratories Limited, first listed with the FDA Mar 2015 and currently FDA-listed.

🏷️ FDA NDC (as labeled) 55111-113-78 billing pads the product segment with a zero
This package
Contains10 capsule, gelatin coated in 1 blister pack Pack sizes2 compare ↓
Also priced by: Part D plans $4.48/unit — full pricing hub ↓
Rx only Generic FDA-listed Non-controlled 🛡 REMS ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Nov 12, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 55111-113-78 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
55111 labeler · 113 product · 78 package
Package marketed since
Mar 9, 2015
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 5511111378 2
FDA record last changed
Nov 12, 2026
⚠️
Other active recalls for Isotretinoin (different manufacturers) — 5 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Apr 6, 2026 — Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin (Teva Pharmaceuticals USA, Inc) · FDA recall D-0521-2026
Class II · Feb 24, 2026 — Failed Dissolution Specifications (MYLAN PHARMACEUTICALS INC) · FDA recall D-0399-2026
Class II · Jan 12, 2026 — Superpotent and Subpotent (Teva Pharmaceuticals USA, Inc) · FDA recall D-0446-2026
Class II · Jan 12, 2026 — Superpotent and Subpotent (Teva Pharmaceuticals USA, Inc) · FDA recall D-0445-2026
Class II · Mar 28, 2024 — Superpotent Drug: The 3-month stability result for assay was found to be above specification limit (Teva Pharmaceuticals USA, Inc) · FDA recall D-0439-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 55111-113-78
Product NDC 55111-113
11-digit billing NDC 55111011378
UNII EH28UP18IF
Application # ANDA202099
SPL Set ID 27b3cf26-f22e-5b70-1c24-009933b7c6ee
Established class (EPC) Retinoid
Chemical class Retinoids
DEA schedule Non-controlled
Marketing category ANDA
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2015-03-09
Route ORAL
Dosage form CAPSULE, GELATIN COATED
Substance ISOTRETINOIN
TE code (Orange Book) AB1 · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 053055
GCN 20383
HICL code 002476
Ingredient (HICL) Isotretinoin
HIC1 code L
Therapeutic class — broad (HIC1) Skin/Subcutaneous Tissue
HIC2 code L1
Therapeutic class — intermediate (HIC2) Drugs To Treat Specific Top Diseases (Systemic)
HIC3 code L1B
Therapeutic class — specific (HIC3) Acne Agents,Systemic
AHFS code 84:28.00.00
AHFS class Keratolytic Agents
FDB label name ZENATANE 30 MG CAPSULE
FDB brand name Zenatane
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 053055
  • GCN: 20383
  • HICL (First Databank): 002476
  • AHFS class code: 84:28.00.00
  • RxCUI (RxNorm): 197843
Why two NDCs? The FDA registers this code as 55111-113-78 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 55111-0113-78. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Retinoid class.

Pharmacologic class Retinoid
Drug family (ATC) Retinoids for topical use in acne, Retinoids for treatment of acne
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ZENATANE 30 MG CAPSULE Ingredient Isotretinoin
📖 What it is MedlinePlus · NLM

Isotretinoin is used to treat severe recalcitrant nodular acne (a certain type of severe acne) that has not been helped by other treatments, such as antibiotics. Isotretinoin is in a class of medications called retinoids. It works by slowing the production of certain natural substances that can cause acne.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats severe nodular acne, meaning deep, inflamed bumps that haven't cleared with other treatments like oral antibiotics. Most products are for patients 12 and older who are no...
  • Most products are taken by mouth twice a day with food, since food helps your body absorb it. Absorica and Absorica LD can be taken with or without meals. Treatment usually lasts 1...
  • Just skip the missed dose. Don't take two doses at once to catch up. Then go back to your regular schedule.
  • What happens if I miss a dose of isotretinoin?
📖 Read our full Isotretinoin guide →
4
Nutrient depletion considerations

Isotretinoin may be associated with lower levels of 4 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $4.48 $448.18 / 100 capsules
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
55111-0113-78 You're viewing this 10 BLISTER PACK in 1 CARTON / 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK Inner NDC 55111-113-79 · each blister pack (10 capsule, gelatin coated) — — 2015-03-09 — Active
55111-0113-81 55111-113-81 Main listing 3 BLISTER PACK in 1 CARTON / 10 CAPSULE, GELATIN COATED in 1 BLISTER PACK Inner NDC 55111-113-79 · each blister pack (10 capsule, gelatin coated) $1.98 / ea $59.45 2015-03-09 — Active

This pack shows little to no recent Medicaid volume — a different pack size carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 10 blister pack in 1 carton / 10 capsule, gelatin coated in 1 blister pack.
What NDC number is used to bill for this package of Zenatane Isotretinoin 30 mg Capsule, Gelatin Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Amnesteem 30 mg 00378-6613-93 Mylan 30 capsules $2.010 AB1 Availability likely —
Claravis 30 mg 00555-1056-86 Teva 10 capsules $2.010 AB1 Availability likely —
Isotretinoin 30 mg 00832-8303-30 Upsher-Smith 10 capsules $2.010 AB1 Availability likely —
Zenatane 30 mg 68001-0654-17 BluePoint 10 capsules $2.010 AB1 Availability likely —
Isotretinoin 30 mg 68308-0783-30 Mayne 10 capsules $2.010 AB1 Availability likely —
Isotretinoin 30 mg 69238-1017-03 Amneal 10 capsules $2.010 AB1 Availability likely —
Isotretinoin 30 mg 70710-1024-08 Zydus 30 capsules $2.010 AB1 Availability likely —
Isotretinoin 30 mg 00245-0573-01 Upsher-Smith 10 capsules $5.428 AB2 Availability likely —
Isotretinoin 30 mg 00591-2435-15 Actavis 30 capsules $5.428 AB2 Availability likely —
Isotretinoin 30 mg 57664-0023-97 Sun 30 capsules $5.428 AB2 Availability likely —
Isotretinoin 30 mg 59651-0634-03 Aurobindo 30 capsules $5.428 AB2 Availability likely —
Isotretinoin 30 mg 68308-0573-30 Mayne 10 capsules $5.428 AB2 Availability likely —
Isotretinoin 30 mg 70710-1577-08 Zydus 30 capsules $5.428 AB2 Availability likely —
Absorica 30 mg 10631-0117-31 Sun 30 capsules $38.236 AB2 Availability likely —
Zenatane 30 mgthis 55111-0113-78 Dr. 10 capsules — AB1 FDA listed —
Isotretinoin 30 mg 69238-1257-03 Amneal 30 capsules — — FDA listed —
Isotretinoin 30 mg 70771-1559-08 Zydus 30 capsules — AB1 FDA listed —
Isotretinoin 30 mg 70771-1665-08 Zydus 30 capsules — AB2 FDA listed —
Accutane 30 mg 72143-0253-30 JG 10 capsules — AB1 FDA listed —
Isotretinoin 30 mg 84386-0010-03 Aurobindo 30 capsules — AB1 FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2015
Listed with the FDA since
Mar 2015
📍
2026
Currently FDA-listed
11 years listed
🔓
·
This is a generic
listed with the FDA
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color Blue / Pink / Green / Red
ShapeOval
ImprintR1
Size5 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Isotretinoin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 5138Q19F1X
    Ammonia is a colorless gas made from nitrogen and hydrogen. It's used in medicines as a pH buffer to maintain the correct acidity level and help keep the product stable.
  • UNII 8PJ61P6TS3
    Butyl alcohol is a clear liquid organic solvent derived from petroleum or natural sources. In medicines, it helps dissolve active ingredients and serves as a solvent in liquid formulations and some topical products.
  • UNII REK4960K2U
    Butylated hydroxyanisole is a synthetic preservative that prevents oils and fats in medicines from spoiling or becoming rancid. It keeps the medicine stable and extends its shelf life.
  • UNII 7FLD91C86K
    Edetate disodium is a chemical compound that binds and removes certain metal ions. In medicines, it acts as a preservative and stabilizer by preventing metals like calcium from interfering with the product's shelf life and consistency.
  • UNII L06K8R7DQK
    A synthetic blue dye approved by the FDA for use in medications and foods. It serves as a colorant to make pills and liquids visually distinct and easier to identify.
  • UNII 1K09F3G675
    Ferric oxide red is an inorganic iron compound used as a colorant in medicines. It gives tablets, capsules, or other dosage forms a red or reddish tint for identification and appearance.
  • UNII EX438O2MRT
    Ferric oxide yellow is a naturally occurring iron compound used as a colorant in medications. It gives tablets, capsules, and other forms a yellow or golden hue for identification and appearance.
  • UNII XM0M87F357
    A dark iron oxide compound that gives medicines their black or dark color. It's used as a colorant in tablets and capsules to help identify the product and make it visually distinctive.
  • UNII 2G86QN327L
    Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII C9H2L21V7U
    A fat derived from coconut or palm oil containing shorter fatty acid chains. It serves as a solvent and carrier to help dissolve or suspend active ingredients, improving absorption and stability in liquid formulations.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
  • UNII 46N107B71O
    Shellac is a natural resin secreted by the lac beetle. It's used as a coating on tablets and capsules to control how quickly the medicine dissolves and to improve appearance and stability.
  • UNII 241ATL177A
    Soybean oil is a natural plant oil derived from soybean seeds. It's used in medicines as a solvent and carrier to help dissolve or suspend active ingredients and improve how the body absorbs them.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
  • UNII 7G1J5DA97F
    White wax is a refined, bleached plant-based or mineral wax that serves as a coating and hardening agent in medicines. It helps control how fast the drug dissolves and improves the product's texture and appearance.

18 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerDr. Reddy's Laboratories Limited
Application holderDR REDDYS LABORATORIES LTD
FDA applicationANDA202099 (ANDA)
Labeler code55111
First marketedMar 2015
Product typeHuman Prescription Drug
Portfolio200 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🚨 Boxed Warning ~1 min read ▾

WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY Zenatane can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of Zenatane even for short periods of time. Potentially any fetus exposed during pregnancy can be affected.

There are no accurate means of determining prenatally whether an exposed fetus has been affected. If pregnancy occurs, discontinue Zenatane immediately and refer the patient to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling [ see Contraindications ( 4 ) , Warnings and Precautions ( 5.1 ) , and Use in Specific Populations ( 8.1 ) ] . Because of the risk of embryo-fetal toxicity, Zenatane is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE REMS [see Warnings and Precautions ( 5.2 )].

WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY See full prescribing information for complete boxed warning. Zenatane can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking Zenatane in any amount, even for short periods of time.

Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. (4, 5.1, 8.1) Zenatane is available only through a restricted program called the iPLEDGE REMS.

(5.2)

🎯 Indications and Usage 210 words ▾

1 INDICATIONS AND USAGE Zenatane is indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, Zenatane is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use : If a second course of Zenatane treatment is needed, it is not recommended before a two-month waiting period because the patient's acne may continue to improve following a 15 to 20-week course of treatment [see Dosage and Administration ( 2.2 )].

Zenatane is a retinoid indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, Zenatane is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. ( 1 ) Limitations of Use:If a second course of Zenatane treatment is needed, it is not recommended before a two-month waiting period because the patient's acne may continue to improve following a 15 to 20-week course of treatment.

(1 )

⏱️ Dosage and Administration ~3 min read ▾

2 DOSAGE AND ADMINISTRATION {template} Evaluations Prior to Prescribing and Use of Zenatane: In patients who can get pregnant, only prescribe Zenatane after verification and documentation that they are not pregnant. See the Full Prescribing Information for the detailed requirements prior to prescribing Zenatane ( 2.1 , 8.3 ) Complete the following laboratory tests in all patients: fasting lipid profile and liver function tests. ( 2.1 ) Recommended dosage is 0.5 to 1 mg/kg/day given in two divided doses with food for 15 to 20 weeks ( 2.2 ) Adult patients with very severe disease (scarring, trunk involvement) may increase dosage to 2 mg/kg/day in two divided doses with food.

( 2.1 ) Once daily dosing is not recommended. (2.2) If a dose is missed, just skip that dose. Do not take two doses at the same time.

(2.2 ) See the Full Prescribing Information for the recommended duration of use (2.3)

2.1Evaluations Prior to Prescribing and Use of Zenatane In patients who can get pregnant, only prescribe Zenatane after verification and documentation that they are not pregnant [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 , 5.2 )]. For the detailed requirements prior to prescribing Zenatane, [see Use in Specific Populations ( 8.3 )] Prior to Zenatane use in all patients, complete the following laboratory testing: A fasting lipid profile including triglycerides [see Warnings and Precautions ( 5.7 , 5.14 )].

Liver function tests [see Warnings and Precautions ( 5.9 , 5.14 )].

2.2Recommended Dosage The recommended dosage range for Zenatane is 0.5 to 1 mg/kg/day given in two divided doses with food for 15 to 20 weeks (see Tables 1 and 2, respectively) [see Clinical Pharmacology ( 12.3 )]. Table 1: Zenatane: Recommended Divided Doses (0.5 mg/kg/day dosage) Body Weight First Dose Second Dose 40 kg 10 mg 10 mg 50 kg 12.5 mg 12.5 mg 60 kg 15 mg 15 mg 70 kg 17.5 mg 17.5 mg 80 kg 20 mg 20 mg 90 kg 22.5 mg 22.5 mg 100 kg 25 mg 25 mg Table 2: Zenatane : Recommended Divided Doses (1 mg/kg/day dosage) Body Weight First Dose Second Dose 40 kg 20 mg 20 mg 50 kg 25 mg 25 mg 60 kg 30 mg 30 mg 70 kg 35 mg 35 mg 80 kg 40 mg 40 mg 90 kg 45 mg 45 mg 100 kg 50 mg 50 mg To decrease the risk of esophageal irritation, instruct patients to swallow the capsules with a full glass of liquid.

Swallow capsules whole. Do not split, crush, chew, or suck on the capsules. During treatment, the dosage may be adjusted according to response of the disease and/or adverse reactions, some of which may be dose-related.

Adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require dosage adjustments up to 2 mg/kg/day for Zenatane in divided doses with food, as tolerated (see Table 3). Table 3: Zenatane : Recommended Divided Doses (2 mg/kg/day dosage) Body Weight First Dose Second Dose 40 kg 40 mg 40 mg 50 kg 50 mg 50 mg 60 kg 60 mg 60 mg 70 kg 70 mg 70 mg 80 kg 80 mg 80 mg 90 kg 90 mg 90 mg 100 kg 100 mg 100 mg The safety and effectiveness of once daily dosing with Zenatane has not been established and is not recommended.

If a dose of Zenatane is missed, just skip that dose. Do not take two doses of Zenatane at the same time.

2.3Recommended Duration of Use A course of treatment is 15 to 20 weeks. If the total nodule count has been reduced by more than 70% prior to completing 15 to 20 weeks of treatment, may discontinue Zenatane. After a period of 2 months or more off treatment, and if warranted by persistent or recurring severe nodular acne, may initiate a second course of Zenatane in patients who have completed skeletal growth.

The use of another course of Zenatane treatment is not recommended before a two-month waiting period because the patient's acne may continue to improve after a 15 to 20-week course of treatment. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth. Long-term use of Zenatane, even in low dosages, has not been studied, and is not recom… [Excerpted — this section continues on DailyMed.]

💊 Dosage Forms and Strengths 120 words ▾

3 DOSAGE FORMS AND STRENGTHS Capsules: 10 mg: Zenatane (isotretinoin capsules USP) 10 mg are opaque blue elliptical soft gelatin capsules imprinted with black ink, “R135” on one side. 20 mg: Zenatane (isotretinoin capsules USP) 20 mg are opaque pink elliptical soft gelatin capsules imprinted with black ink, “R136” on one side. 30 mg: Zenatane (isotretinoin capsules USP) 30 mg are reddish brown colored opaque, elliptical shaped soft gelatin capsule imprinted with “RI” black colored ink along the length of body on one side.

40 mg: Zenatane (isotretinoin capsules USP) 40 mg are opaque green elliptical soft gelatin capsules imprinted with black ink, “R137” on one side. Capsules: 10 mg, 20 mg, 30 mg and 40 mg ( 3 )

⛔ Contraindications 83 words ▾

4 CONTRAINDICATIONS Zenatane is contraindicated in: Pregnancy [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. Patients with hypersensitivity to isotretinoin (or Vitamin A, given the chemical similarity to isotretinoin) or to any of its components (anaphylaxis and other allergic reactions have occurred) [see Warnings and Precautions ( 5.14 )]. Zenatane is contraindicated in: Pregnancy ( 4 , 8.1 ) Patients with hypersensitivity to isotretinoin (or Vitamin A) or any of its components (4.2 , 5.13 )

⚠️ Warnings and Cautions ~3 min read ▾

5 WARNINGS AND PRECAUTIONS Psychiatric Disorders (depression, psychosis, suicidal thoughts and behavior, and aggressive and/or violent behaviors): Prior to and during treatment assess for these conditions; stop if these conditions occur on treatment ( 5.3 ) Intracranial Hypertension (Pseudotumor Cerebri) : Avoid concomitant use with tetracyclines ( 5.4 , 7.2 ) Serious Skin Reactions : Monitor for Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and other serious skin reactions and discontinue treatment if they occur ( 5.5 ) Acute Pancreatitis : If pancreatitis symptoms occur, discontinue treatment ( 5.6 ) Lipid Abnormalities (hypertriglyceridemia, low HDL, and elevation of cholesterol): Monitor lipid levels at regular intervals; stop if hypertriglyceridemia cannot be controlled ( 5.7 ) Hearing Impairment : Discontinue and refer to specialized care ( 5.8 ) Hepatotoxicity : Monitor liver function tests prior to and during treatment ( 5.9 , 5.14 ) Inflammatory Bowel Disease : Discontinue for abdominal pain, rectalbleeding, or severe diarrhea ( 5.10 ) Musculoskeletal Abnormalities : Arthralgias, back pain, decreases in bone mineral density and premature epiphyseal closure ( 5.11 ) Ocular Abnormalities e.g., corneal opacities, decreased night vision: If visual symptoms occur, discontinue, and refer for an ophthalmological exam ( 5.12 )

5.1Embryo-Fetal Toxicity Zenatane is contraindicated in pregnancy [see Contraindications ( 4 )]. Based on human data, Zenatane can cause fetal harm when administered to a pregnant patient. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of Zenatane even for short periods of time.

Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. Major congenital malformations, spontaneous abortions, and premature births have been documented following exposure to isotretinoin during pregnancy [see Use in Specific Populations ( 8.1 )].

If a pregnancy occurs during Zenatane treatment, immediately discontinue Zenatane and refer the patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Immediately report any suspected fetal exposure during or 1 month after Zenatane treatment to the FDA via the MedWatch telephone number 1-800-FDA-1088, and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (www.ipledgeprogram.com). Inform patients not to donate blood during Zenatane treatment and for 1 month following discontinuation because the blood might be given to a pregnant patient whose fetus must not be exposed to isotretinoin.

Zenatane is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) [see Warnings and Precautions ( 5.2 )]. 5.2 iPLEDGE REMS Because of the risk of embryo-fetal toxicity, Zenatane is available only through a restricted program under a REMS called the iPLEDGE REMS [see Warnings and Precautions ( 5.1 )]. Notable requirements of the iPLEDGE REMS include the following: Prescribers must be certified with the REMS and comply with the REMS requirements, including the following: Assess the reproductive status of all patients prior to initiating and during treatment Counsel patients who cannot get pregnant on the risk and REMS requirements prior to initiating treatment.

Counsel patients who can get pregnant on: The risk and REMS requirements prior to and during treatment. Pregnancy prevention requirements prior to and during treatment, or refer patients who can get pregnant to an expert for such counseling Comply with the pregnancy testing requirements. Assess the pregnancy status for patients who can get pregnant by reviewing pregnancy tests and documenting a negative result prior to each prescription.

Report all pregnancies to the REMS. Patients who can become pregnant must be enrolle… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions ~2 min read ▾

6 ADVERSE REACTIONS The following adverse reactions with Zenatane are described in more detail in other sections of the labeling: Embryo-Fetal Toxicity [see Warnings and Precautions ( 5.1 )] Psychiatric Disorders [see Warnings and Precautions ( 5.3 )] Intracranial Hypertension (Pseudotumor Cerebri) [see Warnings and Precautions ( 5.4 )] Serious Skin Reactions [see Warnings and Precautions ( 5.5 )] Pancreatitis [see Warnings and Precautions ( 5.6 )] Lipid Abnormalities [see Warnings and Precautions ( 5.7 )] Hearing Impairment [see Warnings and Precautions ( 5.8 )] Hepatotoxicity [see Warnings and Precautions ( 5.9 )] Inflammatory Bowel Disease [see Warnings and Precautions ( 5.10 )] Musculoskeletal Abnormalities [see Warnings and Precautions ( 5.11 )] Ocular Abnormalities [see Warnings and Precautions ( 5.12 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.13 )] The following adverse reactions, presented alphabetically by body system, associated with the use of Zenatane were identified in clinical studies or postmarketing reports.

Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse Reactions with a Dose Relationship Cheilitis and hypertriglyceridemia were dose related. Body as a Whole Allergic reactions, dry mouth, edema, fatigue, irritability, lymphadenopathy, pain, systemic hypersensitivity, vasculitis, weight loss.

Cardiovascular Palpitation, stroke, tachycardia, vascular thrombotic disease Endocrine/Metabolism and Nutritional Alterations in blood sugar levels, decreased appetite, hypertriglyceridemia, weight fluctuation. Gastrointestinal Abdominal pain, bleeding and inflammation of the gums, colitis, constipation, diarrhea, esophageal ulceration, esophagitis, ileitis, nausea, hepatitis, inflammatory bowel disease, other nonspecific gastrointestinal symptoms, pancreatitis, vomiting. Hematologic Anemia, neutropenia including severe neutropenia, rare reports of agranulocytosis, thrombocytopenia.

Infections and Infestations Infections (including disseminated herpes simplex, hordeolum, nasopharyngitis, upper respiratory tract infections). Laboratory Abnormalities The following lab test values were increased: alkaline phosphatase, ALT, AST, bilirubin, cholesterol, CPK, fasting blood glucose, gamma-glutamyltransferase, LDH, LDL, platelet counts, sedimentation rate, triglycerides, and uric acid (hyperuricemia). The following lab test values were decreased: high density lipoprotein (HDL), RBC parameters, and WBC counts.

Urine findings included increased microscopic or gross hematuria, proteinuria, white cells. Musculoskeletal and Connective Tissue Arthritis, calcification of tendons and ligaments; decreases in bone mineral density; elevations of CPK/rare reports of rhabdomyolysis musculoskeletal symptoms (sometimes severe) including arthralgia, back pain, extremity pain, musculoskeletal pain or stiffness, myalgia, neck pain [see Warnings and Precautions ( 5.11 )]; other types of bone abnormalities; premature epiphyseal closure; skeletal hyperostosis; tendonitis; and transient chest pain.

Neurological Dizziness, drowsiness, intracranial hypertension (pseudotumor cerebri), headache, insomnia, lethargy, malaise, nervousness, paresthesia, seizures, syncope, stroke, and weakness. Psychiatric Aggression, auditory hallucinations, anger, depression, emotional instability, insomnia, irritability, panic attack, psychosis, suicidal ideation, suicide, suicide attempts, violent behaviors. In some patients who reported depression, their depression subsided with discontinuation of Zenatane treatment but recurred with reinstitution of Zenatane treatment Reproductive System Abnormal menses, sexual dysfunction that may continue after discontinuation of treatment (including erectile dysfunction, decreased libido, decreased vaginal lubrication, and vaginal dryness).

Respira… [Excerpted — this section continues on DailyMed.]

🔄 Drug Interactions 146 words ▾

7 DRUG INTERACTIONS Vitamin A : Avoid concomitant use (7.1) Tetracyclines : Avoid concomitant use (7.2)

7.1Vitamin A Avoid concomitant use of Zenatane with supplements containing vitamin A. Zenatane is closely related to vitamin A. Therefore, concomitant use of Zenatane with vitamin A may lead to Zenatane-related adverse reactions.

7.2Tetracyclines Avoid concomitant use of Zenatane with tetracyclines. Zenatane use has been associated with a number of cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use with tetracyclines [see Warnings and Precautions ( 5.4 )].

7.3Oral Contraceptives It is not known if there is an interaction between Zenatane with oral contraceptives that do not contain norethindrone and ethinyl estradiol. Zenatane did not result in clinically significant changes in the pharmacokinetics of norethindrone and ethinyl estradiol when used concomitantly with norethindrone and ethinyl estradiol oral contraceptive [see Clinical Pharmacology ( 12.3 )]

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Lactation : Breastfeeding not recommended ( 8.2 ). In Patients Who Can Get Pregnant : Pregnancy testing is required prior to, during, and after Zenatane treatment. See the Full Prescribing Information for the detailed pregnancy test and contraception requirements. ( 8.3).

8.1Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that documents pregnancies in patients exposed to isotretinoin during pregnancy. Report any suspected fetal exposure during or 1 month after Zenatane treatment immediately to the FDA via the MedWatch telephone number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (www.ipledgeprogram.com). Risk Summary Zenatane is contraindicated during pregnancy because isotretinoin can cause fetal harm when administered to a pregnant patient.

There is an increased risk of major congenital malformations, spontaneous abortions, and premature births following isotretinoin exposure during pregnancy in humans [see Warnings and Precautions ( 5.1 )]. If Zenatane is used during pregnancy, or if the patient becomes pregnant while taking Zenatane, apprise the patient of the potential hazard to a fetus. If pregnancy occurs during treatment of a patient who is taking Zenatane, immediately discontinue Zenatane and refer the patient to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.

Data Human Data : Major congenital malformations that have been documented following Zenatane exposure include malformations of the face, eyes, ears, skull, central nervous system (CNS), cardiovascular system, and thymus and parathyroid glands. External malformations include: skull; ear (including anotia, micropinna, small or absent external auditory canals); eye (including microphthalmia); facial dysmorphia and cleft palate. Internal abnormalities include: CNS (including cerebral and cerebellar malformations, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular; thymus gland; parathyroid hormone deficiency.

In some cases, death has occurred as a result of the malformations. Cases of IQ scores less than 85 with or without other abnormalities have been reported in children exposed in utero to isotretinoin. An increased risk of spontaneous abortion and premature births have been reported with isotretinoin exposure during pregnancy.

8.2Lactation Risk Summary There are no data on the presence of isotretinoin in either animal or human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in nursing infants from isotretinoin, advise patients that breastfeeding is not recommended during treatment with Zenatane, and for at least 8 days after the last dose of Zenatane.

8.3Females and Males of Reproductive Potential All patients who can become pregnant must comply with the iPLEDGE REMS requirements [see Warnings and Precautions (5.2)]. Pregnancy Testing In patients who can get pregnant, pregnancy testing is required prior to, during, and after Zenatane treatment. Pregnancy Testing Prior to Prescribing Zenatane: In patients who can get pregnant, only prescribe Zenatane after verification and documentation that they are not pregnant: (1) Complete the first urine or serum pregnancy test (screening test) in a medical setting (e.g., prescriber’s office, clinic, laboratory) and verify and document that the test is negative, AND (2) For patients with: Regular menstrual cycles, complete the second urine or serum pregnancy test (confirmatory test) in a medical setting (1) at least 30 days after the screening test and during the first five days of their menstrual period immediately preceding the beginning of Zenatane treatment, AND (2) after the patient has used their chosen pregnancy prevention methods (i.e., two forms of contraception or committed to abstinence) for at least 30 days.

Verify and document that the confirma… [Excerpted — this section continues on DailyMed.]

🤰 Pregnancy ~1 min read ▾

8.1Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that documents pregnancies in patients exposed to isotretinoin during pregnancy. Report any suspected fetal exposure during or 1 month after Zenatane treatment immediately to the FDA via the MedWatch telephone number 1-800-FDA-1088 and also to the iPLEDGE pregnancy registry at 1-866-495-0654 or via the internet (www.ipledgeprogram.com). Risk Summary Zenatane is contraindicated during pregnancy because isotretinoin can cause fetal harm when administered to a pregnant patient.

There is an increased risk of major congenital malformations, spontaneous abortions, and premature births following isotretinoin exposure during pregnancy in humans [see Warnings and Precautions ( 5.1 )]. If Zenatane is used during pregnancy, or if the patient becomes pregnant while taking Zenatane, apprise the patient of the potential hazard to a fetus. If pregnancy occurs during treatment of a patient who is taking Zenatane, immediately discontinue Zenatane and refer the patient to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.

Data Human Data : Major congenital malformations that have been documented following Zenatane exposure include malformations of the face, eyes, ears, skull, central nervous system (CNS), cardiovascular system, and thymus and parathyroid glands. External malformations include: skull; ear (including anotia, micropinna, small or absent external auditory canals); eye (including microphthalmia); facial dysmorphia and cleft palate. Internal abnormalities include: CNS (including cerebral and cerebellar malformations, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular; thymus gland; parathyroid hormone deficiency.

In some cases, death has occurred as a result of the malformations. Cases of IQ scores less than 85 with or without other abnormalities have been reported in children exposed in utero to isotretinoin. An increased risk of spontaneous abortion and premature births have been reported with isotretinoin exposure during pregnancy.

🧒 Pediatric Use ~2 min read ▾

8.4Pediatric Use The safety and effectiveness of Zenatane for the treatment of severe recalcitrant nodular acne have been established in non-pregnant pediatric patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater who are unresponsive to conventional treatment, including systemic antibiotics. Use of Zenatane in this age group for this indication is supported by evidence from a clinical trial comparing 103 pediatric patients (13 to 17 years) to 197 adults (both with severe recalcitrant nodular acne).

Results from this study demonstrated that Zenatane, at a dosage of 1 mg/kg/day given in two divided doses, was similarly effective in treating severe recalcitrant nodular acne in both pediatric and adult patients. The safety and effectiveness of Zenatane in pediatric patients less than 12 years of age have not been established. Adverse Reactions in Pediatric Patients In trials with Zenatane, adverse reactions reported in pediatric patients aged 12 to 17 years old were similar to those described in adults except for the increased incidence of back pain and arthralgia (both of which were sometimes severe) and myalgia in pediatric patients.

In a trial of pediatric patients aged 12 to 17 years old treated with Zenatane, approximately 29% (104/358) developed back pain. Back pain was severe in 14% (14/104) of the cases and occurred at a higher frequency in female patients than male patients. Arthralgias occurred in 22% (79/358) of pediatric patients including severe arthralgias in 8% (6/79) of patients.

Evaluate the musculoskeletal system in pediatric patients 12 years of age and older who present with these symptoms during or after a course of Zenatane. Consider discontinuing Zenatane if any significant abnormality is found. Effects on Bone Mineral Density in Pediatric Patients In an open-label clinical trial (N=217) of a single course of treatment with Zenatane for adolescents with severe recalcitrant nodular acne, BMD at several skeletal sites were assessed: One patient had a decrease in lumbar spine BMD >4% based on unadjusted data; 16 (8%) patients had decreases in lumbar spine BMD >4%, and all the other patients (92%) did not have significant decreases or had increases (adjusted for body mass index).

Nine patients (5%) had a decrease in total hip BMD >5% based on unadjusted data. Twenty-one (11%) patients had decreases in total hip BMD >5%, and all the other patients (89%) did not have significant decreases or had increases (adjusted for body mass index). Follow-up trials performed in 8 of the patients with decreased BMD for up to 11 months thereafter demonstrated increasing BMD in 5 patients at the lumbar spine, while the other 3 patients had lumbar spine BMD measurements below baseline values.

Total hip BMD remained below baseline (range -1.6% to -7.6%) in 5 of 8 patients (63%). In a separate open-label extension trial of 10 patients including those ages 13 to 17 years, who started a second course of Zenatane 4 months after the first course, two patients showed a decrease in mean lumbar spine BMD up to 3.3%. Epiphyseal Closure There have been spontaneous literature reports of premature epiphyseal closure in acne patients who received the recommended dosage of Zenatane.

The effect of multiple courses of Zenatane on epiphyseal closure is unknown [see Warnings and Precautions ( 5.11 )].

🧓 Geriatric Use 42 words ▾

8.5Geriatric Use Clinical studies of Zenatane did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. The effects of aging may increase some risks associated with Zenatane treatment.

🆘 Overdosage 118 words ▾

10 OVERDOSAGE Isotretinoin overdosage has been associated with vomiting, facial flushing, cheilosis, abdominal pain, headache, dizziness, and ataxia. Evaluate patients who can become pregnant who present with an isotretinoin overdosage for pregnancy. Because an overdosage would be expected to result in higher levels of isotretinoin in semen than found during a normal treatment course, instruct male patients treated with Zenatane to use a condom, or avoid reproductive sexual activity with a patient who is or might become pregnant, for 1 month after the overdose.

Instruct all patients with Zenatane overdose not donate blood for at least 1 month. If an overdose occurs, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

🧬 Clinical Pharmacology ~3 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action The exact mechanism of action of Zenatane in the treatment of severe recalcitrant nodular acne in nonpregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater who are unresponsive to conventional therapy, including systemic antibiotics is unknown. Isotretinoin, a retinoid, inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion.

The decrease in sebum secretion is temporary and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation.

12.2Pharmacodynamics Decreased sebum secretion is related to the dose and duration of treatment with Zenatane.

12.3Pharmacokinetics The following parameters are presented as mean [coefficient of variation (CV%)] following a single oral dose of 80 mg of Zenatane in healthy adult subjects unless otherwise stated. Isotretinoin C max is 862 (22%) ng/mL and AUC 0-inf is 10,004 (22%) ng*h/mL when Zenatane was administered with food in healthy adults. Isotretinoin accumulation ratio ranged from 0.90 to 5.43 in patients with cystic acne after multiple doses.

No clinically significant differences in the pharmacokinetics of isotretinoin were observed between patients with nodular acne and healthy subjects without acne. Absorption Isotretinoin time to maximum concentration (T max ) is 5.3 hours (77%) when administered with food. Effect on Food: Isotretinoin AUC 0-inf increased 2.7-fold and C max increased 2.9-fold relative to the fasted state following a high-fat meal.

In addition, the extent of formation of all metabolites was higher, T max increased to 5.3 hours (77%), and the elimination half-life was unchanged under fed conditions [see Dosage and Administration ( 2.1 )]. Distribution Isotretinoin is more than 99.9% bound to plasma proteins, primarily to albumin. Elimination The mean ± SD elimination half-life of isotretinoin is 21± 8.2 hours and 24 ± 5.3 hours for its 4-oxo-isotretinoin metabolite.

Metabolism: Isotretinoin is primarily metabolized by CYP2C8, 2C9, 3A4, and 2B6 in vitro. Isotretinoin and its metabolites are further metabolized into conjugates. Isotretinoin is metabolized into at least three metabolites (4-oxo-isotretinoin, retinoic acid (tretinoin), and 4-oxoretinoic acid (4-oxo-tretinoin)) which are detected in human plasma.

Retinoic acid and 13-cis-retinoic acid are geometric isomers and show reversible interconversion. The administration of one isomer will give rise to the other. Isotretinoin is also irreversibly oxidized to 4-oxo-isotretinoin, which forms its geometric isomer 4-oxo-tretinoin.

The exposure of adult cystic acne patients to 4-oxo-isotretinoin at steady state under fasted and fed conditions was approximately 3.4 times higher than that of isotretinoin. All of these metabolites possess retinoid activity in vitro, however the clinical significance is unknown. Excretion: Following administration of 80 mg of radiolabeled isotretinoin as a liquid suspension, the metabolites of isotretinoin were excreted in feces and urine in relatively equal amounts (total of 65% to 83%).

Specific Populations Pediatric Patients: No clinically statistically significant differences in isotretinoin pharmacokinetics were observed based on age (12 to 15 years, and ≥18 years) in patients who received single and multiple doses of Zenatane. In both age groups, 4-oxo-isotretinoin was the major metabolite compared to tretinoin and 4-oxo-tretinoin. Drug Interaction Studies Clinical Studies: Norethindrone and Ethinyl Estradiol: There were no clinically significant differences in the pharmacokinetics of norethindrone and ethinyl estradiol after the concomitant use of Zenatane (dosage of 1 mg/kg/day) with an oral contraceptive agent in premenopausal female patients with severe recalcitrant nodular acne.

Additionally, there was no clinically significant difference… [Excerpted — this section continues on DailyMed.]

🧬 Mechanism of Action 97 words ▾

12.1Mechanism of Action The exact mechanism of action of Zenatane in the treatment of severe recalcitrant nodular acne in nonpregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater who are unresponsive to conventional therapy, including systemic antibiotics is unknown. Isotretinoin, a retinoid, inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion.

The decrease in sebum secretion is temporary and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation.

📦 How Supplied / Storage and Handling ~1 min read ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Zenatane (isotretinoin capsules, USP) is supplied as follows: Zenatane (isotretinoin capsules USP) 10 mg are opaque blue elliptical soft gelatin capsules imprinted with black ink, “R135” on one side and are supplied in boxes of 30 containing 3 prescription packs of 10 capsules and in boxes of 100 containing 10 prescription packs of 10 capsules, as unit dose blisters. Boxes of 30 (3 Prescription Packs of 10 capsules) NDC 55111-135-81 Boxes of 100 (10 Prescription Packs of 10 capsules) NDC 55111-135-78 Zenatane (isotretinoin capsules USP) 20 mg are opaque pink elliptical soft gelatin capsules imprinted with black ink, “R136” on one side and are supplied in boxes of 30 containing 3 prescription packs of 10 capsules and in boxes of 100 containing 10 prescription packs of 10 capsules, as unit dose blisters.

Boxes of 30 (3 Prescription Packs of 10 capsules) NDC 55111-136-81 Boxes of 100 (10 Prescription Packs of 10 capsules) NDC 55111-136-78 Zenatane (isotretinoin capsules USP) 30 mg are reddish brown colored opaque, elliptical shaped soft gelatin capsule imprinted with “RI” black colored ink along the length of body on one side and are supplied in boxes of 30 containing 3 prescription packs of 10 capsules and in boxes of 100 containing 10 prescription packs of 10 capsules, as unit dose blisters. Boxes of 30 (3 Prescription Packs of 10 capsules) NDC 55111-113-81 Boxes of 100 (10 Prescription Packs of 10 capsules) NDC 55111-113-78 Zenatane (isotretinoin capsules USP) 40 mg are opaque green elliptical soft gelatin capsules imprinted with black ink, “R137” on one side and are supplied in boxes of 30 containing 3 prescription packs of 10 capsules and 100 containing 10 prescription packs of 10 capsules, as unit dose blisters.

Boxes of 30 (3 prescription packs of 10 capsules) NDC 55111-137-81 Boxes of 100(10 prescription packs of 10 capsules) NDC 55111-137-78 Store at 20° to 25°C (68° to 77°F). [See USP controlled room temperature]. Protect from light.

📋 Description 186 words ▾

11 DESCRIPTION Chemically, isotretinoin is 13-cis-retinoic acid and is related to both retinoic acid and retinol (vitamin A). It is a yellow to slightly orange crystalline powder with a molecular weight of 300.44. Isotretinoin has high lipophilicity.

The structural formula is: Zenatane (isotretinoin capsules, USP) contains 10 mg, 20 mg, 30 mg, or 40 mg of isotretinoin (a retinoid) for oral administration. In addition to the active ingredient, isotretinoin, each capsule contains the following inactive ingredients: butylated hydroxyanisole, edetate disodium, hydrogenated vegetable oil (Type-I and Type-II), medium chain triglyceride, refined soybean oil and white wax. Gelatin capsules contain ferric oxide red, ferric oxide yellow (for 30 mg), gelatin, glycerin, methyl paraben, propyl paraben, lake blend blue (LB-332) containing D&C Yellow No.10, FD&C Blue No.1 (for 10 mg), lake blend red (LB-1574) containing D&C Red No.27, D&C Red No.30 (for 20 mg), lake blend green (LB-333) containing D&C Yellow No.10, FD&C Blue No.1 (for 40 mg), lake blend white (TLB-1774) containing FD&C Blue No.2, titanium dioxide, and opacode black S-1-17823 containing iron oxide black, N-butyl alcohol, propylene glycol, ammonium hydroxide and shellac.

Meets USP Dissolution Test 5.

💬 Information for Patients ~3 min read ▾

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Embryo-Fetal Toxicity There is an extremely high risk of life-threatening birth defects when Zenatane is used in pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. Instruct patients who can become pregnant that they must not be pregnant during or up to one month after Zenatane treatment.

Instruct patients to not donate blood during Zenatane treatment and for 1 month following discontinuation to avoid blood donation to a pregnant patient. iPLEDGE REMS Zenatane is available only through a restricted program called the iPLEDGE REMS [see Warnings and Precautions ( 5.2 )]. Inform patients who can get pregnant of the following notable requirements. These patients must: Enroll in the REMS Comply with REMS requirements, including: Comply with the pregnancy testing and pregnancy prevention requirements [see Use in Specific Populations ( 8.3 )] Demonstrate comprehension of the risk and REMS requirements prior to each prescription Obtain the prescription within the 7-day prescription window (i.e., within 7 days of the pregnancy test collection) Inform their health care provider if they become pregnant and stop treatment.

Inform patients who cannot get pregnant of the following notable requirements. These patients must enroll in the REMS and comply with the REMS requirements. Zenatane is available only from certified pharmacies participating in the REMS.

Therefore, provide patients with the telephone number and website for information on how to obtain Zenatane [see Warnings and Precautions ( 5.2 )]. Lactation Because of the potential for serious adverse reactions in nursing infants from isotretinoin, advise patients that breastfeeding is not recommended during treatment with Zenatane, and for at least 8 days after the last dose of Zenatane [see Use in Specific Populations ( 8.2 )]. Psychiatric Disorders Instruct patients and/or their caregivers/families that Zenatane may cause depression, psychosis, suicidal ideation, suicide attempts, and aggressive or violent behavior.

Instruct patients to stop Zenatane and to contact a health care provider if they develop any of these signs or symptoms [see Warnings and Precautions ( 5.3 )]. Important Administration Instructions To decrease the risk of esophageal irritation, instruct patients to swallow the capsules with a full glass of liquid. Instruct patients to administer this Zenatane product with food [see Dosage and Administration ( 2.1 )].

Intracranial Hypertension (Pseudotumor Cerebri) Advise patients that intracranial hypertension (pseudotumor cerebri) has occurred with Zenatane use including concomitant use with tetracyclines. Thus, advise patients to avoid concomitant use with tetracyclines and to discontinue Zenatane immediately if they have symptoms of intracranial hypertension [see Warnings and Precautions ( 5.4 )]. Serious Skin Reactions Advise patients that severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported in patients treated with isotretinoin and to discontinue Zenatane if clinically significant skin reactions occur [see Warnings and Precautions ( 5.5) ].

Inflammatory Bowel Disease Advise patients that inflammatory bowel disease (including regional ileitis) have occurred with isotretinoin use including those without a prior history of IBD and if they experience IBD symptoms, to discontinue Zenatane immediately [see Warnings and Precautions ( 5.10 )]. Musculoskeletal Abnormalities Inform patients that: There have been reports of osteoporosis and fractures and that isotretinoin may have a negative effect on bone mineral density [see Warnings and Precautions ( 5.11 )]. Isotretinoin use has been associated with musculoskeletal abnormalities (e.g., arthralgia, back pain) [see Warnings and Precautions ( 5.11 )].

Inform pediatric patients and their families that isotretinoin use in pediatric pati… [Excerpted — this section continues on DailyMed.]

💬 Medication Guide ~3 min read ▾

MEDICATION GUIDE ZENATANE TM ( ZEN – a – tān) (isotretinoin capsules), for oral use Read the Medication Guide that comes with Zenatane before you start taking it and each time you get a prescription. There may be new information. This information does not take the place of talking with your health care provider about your medical condition or your treatment.

What is the most important information I should know about Zenatane? Zenatane can harm your unborn baby, including birth defects (deformed babies), loss of a baby before birth (miscarriage), death of the baby, and early (premature) births. Patients who are pregnant or who plan to become pregnant must not take Zenatane.

Because of the risk of birth defects , Zenatane is only available through a special program called the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). Your healthcare provider must be enrolled in the iPLEDGE REMS for you to be prescribed Zenatane. Before you start treatment with Zenatane, you must enroll in the iPLEDGE REMS.

You must understand and agree to do everything required in the iPLEDGE REMS. Patients must not get pregnant: for 1 month before starting Zenatane during treatment with Zenatane for 1 month after stopping Zenatane If you get pregnant during treatment with Zenatane, stop taking it right away and tell your health care provider. Health care providers and patients should report all cases of pregnancy that happen during treatment or 1 month after stopping treatment to: FDA MedWatch at 1-800-FDA-1088, and the iPLEDGE Pregnancy Registry at 1-866-495-0654 or www.ipledgeprogram.com If you have any questions about the iPLEDGE REMS, ask your healthcare provider, or go to www.ipledgeprogram.com or call 1-866-495-0654.

Serious mental health problems , including: depression psychosis (seeing or hearing things that are not real) suicide. Some patients taking Zenatane have had thoughts about hurting themselves or putting an end to their own lives (suicidal thoughts). Some people tried to end their own lives.

Some people have ended their own lives. Stop taking Zenatane and tell your health care provider right away if you or a family member notices that you get any of the following signs and symptoms of depression or psychosis: start to feel sad or have crying spells lose interest in activities you once enjoyed sleep too much or have trouble sleeping become more irritable, angry, or aggressive than usual (for example, temper outbursts, thoughts of violence) have a change in your appetite or body weight suicide attempts have trouble concentrating withdraw from your friends or family feel like you have no energy have feelings of worthlessness or guilt start having thoughts about hurting yourself or taking your own life (suicidal thoughts) start acting on dangerous impulses start seeing or hearing things that are not real Your health care provider may tell you to see a mental health care professional if you have any of these symptoms.

See “ What are the possible side effects of Zenatane?” for more information about side effects. What is Zenatane? Zenatane is a prescription medicine used in patients 12 years of age and older, who are not pregnant, for the treatment of severe acne (nodular acne) that cannot be cleared up by any other acne treatments, including antibiotics.

Zenatane can cause serious side effects (see “What is the most important information I should know about Zenatane?” ). Zenatane can only be: prescribed by health care providers that are enrolled in the iPLEDGE REMS dispensed by a pharmacy that is enrolled in the iPLEDGE REMS given to patients who are enrolled in the iPLEDGE REMS and agree to do everything required in the program. It is not known if Zenatane is safe and effective in children less than 12 years of age.

Do not take Zenatane if you: are pregnant, plan to become pregnant, or become pregnant during Zenatane treatment. Zenatane can cause life-threatening birth defects. See “What is the most important information I should kno… [Excerpted — this section continues on DailyMed.]

🍼 Nursing Mothers ~3 min read ▾

8.3Females and Males of Reproductive Potential All patients who can become pregnant must comply with the iPLEDGE REMS requirements [see Warnings and Precautions (5.2)]. Pregnancy Testing In patients who can get pregnant, pregnancy testing is required prior to, during, and after Zenatane treatment. Pregnancy Testing Prior to Prescribing Zenatane: In patients who can get pregnant, only prescribe Zenatane after verification and documentation that they are not pregnant: (1) Complete the first urine or serum pregnancy test (screening test) in a medical setting (e.g., prescriber’s office, clinic, laboratory) and verify and document that the test is negative, AND (2) For patients with: Regular menstrual cycles, complete the second urine or serum pregnancy test (confirmatory test) in a medical setting (1) at least 30 days after the screening test and during the first five days of their menstrual period immediately preceding the beginning of Zenatane treatment, AND (2) after the patient has used their chosen pregnancy prevention methods (i.e., two forms of contraception or committed to abstinence) for at least 30 days.

Verify and document that the confirmatory test is negative, OR Amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding , complete the second urine or serum pregnancy test (confirmatory test) in a medical setting (1) at least 30 days after the screening test and immediately preceding the beginning of Zenatane treatment, AND (2) after the patient has used their chosen pregnancy prevention methods (i.e., two forms of contraception or committed to abstinence) for at least 30 days.

Verify and document that the confirmatory test is negative. If a patient who can get pregnant has had negative screening and confirmatory pregnancy tests but they missed the 7-day prescription window (the patient has not obtained their Zenatane prescription starting from the day of the pregnancy test through six days after the day of the pregnancy test) and have not started Zenatane treatment, repeat a urine or serum pregnancy test in a medical setting and verify and document that this repeat test is negative prior to prescribing Zenatane.

The confirmatory pregnancy test must be repeated, as needed, until the patient receives Zenatane. Pregnancy Testing During Treatment with Zenatane: In patients who can get pregnant who are being treated with Zenatane, within 7-days before each prescription obtain a urine or serum pregnancy test in a medical setting (e.g., prescriber’s office, laboratory, clinic) or instruct patients to use a home pregnancy test. If the patient who can get pregnant missed the 7-day prescription window (the patient has not obtained their Zenatane prescription starting from the day of the pregnancy test through six days after the day of the pregnancy test), repeat the urine or serum pregnancy test within seven days before the next prescription in a medical setting or instruct patients to use a home pregnancy test.

Verify and document the negative pregnancy test result prior to the prescribing additional Zenatane treatment. Pregnancy Testing in Patients Who Have Completed Zenatane Treatment: In patients can get pregnant who have completed Zenatane treatment, complete a urine or serum pregnancy test in a medical setting (e.g., prescriber’s office, laboratory, clinic) or instruct patients to use a home pregnancy test:At the end of the entire course of Zenatane treatment, ANDOne month after the discontinuation of Zenatane. Contraception Patients who can get pregnant must use two forms of contraception simultaneously, at least one of which must be a primary form (see Table 4), for at least one month prior to initiation of Zenatane treatment, during Zenatane treatment, and for one month after discontinuing Zenatane treatment.

However, two forms of contraception are not required if the patient commits to continuous abstinence from not having any sexual contact with a partner which may result in pre… [Excerpted — this section continues on DailyMed.]

🧬 Pharmacokinetics ~2 min read ▾

12.3Pharmacokinetics The following parameters are presented as mean [coefficient of variation (CV%)] following a single oral dose of 80 mg of Zenatane in healthy adult subjects unless otherwise stated. Isotretinoin C max is 862 (22%) ng/mL and AUC 0-inf is 10,004 (22%) ng*h/mL when Zenatane was administered with food in healthy adults. Isotretinoin accumulation ratio ranged from 0.90 to 5.43 in patients with cystic acne after multiple doses.

No clinically significant differences in the pharmacokinetics of isotretinoin were observed between patients with nodular acne and healthy subjects without acne. Absorption Isotretinoin time to maximum concentration (T max ) is 5.3 hours (77%) when administered with food. Effect on Food: Isotretinoin AUC 0-inf increased 2.7-fold and C max increased 2.9-fold relative to the fasted state following a high-fat meal.

In addition, the extent of formation of all metabolites was higher, T max increased to 5.3 hours (77%), and the elimination half-life was unchanged under fed conditions [see Dosage and Administration ( 2.1 )]. Distribution Isotretinoin is more than 99.9% bound to plasma proteins, primarily to albumin. Elimination The mean ± SD elimination half-life of isotretinoin is 21± 8.2 hours and 24 ± 5.3 hours for its 4-oxo-isotretinoin metabolite.

Metabolism: Isotretinoin is primarily metabolized by CYP2C8, 2C9, 3A4, and 2B6 in vitro. Isotretinoin and its metabolites are further metabolized into conjugates. Isotretinoin is metabolized into at least three metabolites (4-oxo-isotretinoin, retinoic acid (tretinoin), and 4-oxoretinoic acid (4-oxo-tretinoin)) which are detected in human plasma.

Retinoic acid and 13-cis-retinoic acid are geometric isomers and show reversible interconversion. The administration of one isomer will give rise to the other. Isotretinoin is also irreversibly oxidized to 4-oxo-isotretinoin, which forms its geometric isomer 4-oxo-tretinoin.

The exposure of adult cystic acne patients to 4-oxo-isotretinoin at steady state under fasted and fed conditions was approximately 3.4 times higher than that of isotretinoin. All of these metabolites possess retinoid activity in vitro, however the clinical significance is unknown. Excretion: Following administration of 80 mg of radiolabeled isotretinoin as a liquid suspension, the metabolites of isotretinoin were excreted in feces and urine in relatively equal amounts (total of 65% to 83%).

Specific Populations Pediatric Patients: No clinically statistically significant differences in isotretinoin pharmacokinetics were observed based on age (12 to 15 years, and ≥18 years) in patients who received single and multiple doses of Zenatane. In both age groups, 4-oxo-isotretinoin was the major metabolite compared to tretinoin and 4-oxo-tretinoin. Drug Interaction Studies Clinical Studies: Norethindrone and Ethinyl Estradiol: There were no clinically significant differences in the pharmacokinetics of norethindrone and ethinyl estradiol after the concomitant use of Zenatane (dosage of 1 mg/kg/day) with an oral contraceptive agent in premenopausal female patients with severe recalcitrant nodular acne.

Additionally, there was no clinically significant differences in the serum levels of progesterone, folliclestimulating hormone, and luteinizing hormone in in these patients. Phenytoin: There was no clinically significant differences in the pharmacokinetics of phenytoin when used concomitantly with isotretinoin.

🧬 Pharmacodynamics 16 words ▾

12.2Pharmacodynamics Decreased sebum secretion is related to the dose and duration of treatment with Zenatane.

🧪 Nonclinical Toxicology ~2 min read ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenesis In male and female Fischer 344 rats given oral isotretinoin at dosages of 8 or 32 mg/kg/day (1.3 or 5.3 times the recommended clinical Zenatane dosage of 1 mg/kg/day, after normalization for total body surface area) for greater than 18 months, there was a dose-related increased incidence of pheochromocytoma relative to controls. The incidence of adrenal medullary hyperplasia was also increased at the higher dosage in both sexes. The relatively high level of spontaneous pheochromocytomas occurring in the male Fischer 344 rat makes it an equivocal model for study of this tumor; therefore, the relevance of this tumor to humans is uncertain.

Mutagenesis The Ames test was conducted with isotretinoin in two laboratories. The results of the tests in one laboratory were negative, while in the second laboratory, a weakly positive response (less than 1.6 times background) was noted in S. typhimurium TA100 when the assay was conducted with metabolic activation. No dose response effect was seen, and all other strains were negative.

Additionally, other tests designed to assess genotoxicity (Chinese hamster cell assay, mouse micronucleus test, S. cerevisiae D7 assay, in vitro clastogenesis assay with human-derived lymphocytes, and unscheduled DNA synthesis assay) were all negative. Impairment of Fertility In rats, no adverse effects on gonadal function, fertility, conception rate, gestation or parturition were observed at oral dosages of isotretinoin of 2, 8, or 32 mg/kg/day (0.3, 1.3, or 5.3 times the recommended clinical Zenatane dosage of 1 mg/kg/day, after normalization for total body surface area).

In dogs, testicular atrophy was noted after treatment with oral isotretinoin for approximately 30 weeks at dosages of 20 or 60 mg/kg/day (10 or 30 times the recommended clinical Zenatane dosage of 1 mg/kg/day, after normalization for total body surface area). In general, there was microscopic evidence for appreciable depression of spermatogenesis, but some sperm were observed in all testes examined, and in no instance were completely atrophic tubules seen.

13.2Animal Toxicology and/or Pharmacology In rats given 8 or 32 mg/kg/day of isotretinoin (1.3 or 5.3 times the recommended clinical Zenatane dosage of 1 mg/kg/day, respectively, after normalization for total body surface area) for 18 months or longer, the incidences of focal calcification, fibrosis and inflammation of the myocardium, calcification of coronary, pulmonary and mesenteric arteries, and metastatic calcification of the gastric mucosa were greater than in control rats of similar age. Focal endocardial and myocardial calcifications associated with calcification of the coronary arteries were observed in two dogs after approximately 6 to 7 months of treatment with isotretinoin at a dosage of 60 to 120 mg/kg/day (30 to 60 times the recommended clinical Zenatane dosage of 1 mg/kg/day, after normalization for total body surface area).

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ~1 min read ▾

13.1Carcinogenesis, Mutagenesis, and Impairment of Fertility Carcinogenesis In male and female Fischer 344 rats given oral isotretinoin at dosages of 8 or 32 mg/kg/day (1.3 or 5.3 times the recommended clinical Zenatane dosage of 1 mg/kg/day, after normalization for total body surface area) for greater than 18 months, there was a dose-related increased incidence of pheochromocytoma relative to controls. The incidence of adrenal medullary hyperplasia was also increased at the higher dosage in both sexes. The relatively high level of spontaneous pheochromocytomas occurring in the male Fischer 344 rat makes it an equivocal model for study of this tumor; therefore, the relevance of this tumor to humans is uncertain.

Mutagenesis The Ames test was conducted with isotretinoin in two laboratories. The results of the tests in one laboratory were negative, while in the second laboratory, a weakly positive response (less than 1.6 times background) was noted in S. typhimurium TA100 when the assay was conducted with metabolic activation. No dose response effect was seen, and all other strains were negative.

Additionally, other tests designed to assess genotoxicity (Chinese hamster cell assay, mouse micronucleus test, S. cerevisiae D7 assay, in vitro clastogenesis assay with human-derived lymphocytes, and unscheduled DNA synthesis assay) were all negative. Impairment of Fertility In rats, no adverse effects on gonadal function, fertility, conception rate, gestation or parturition were observed at oral dosages of isotretinoin of 2, 8, or 32 mg/kg/day (0.3, 1.3, or 5.3 times the recommended clinical Zenatane dosage of 1 mg/kg/day, after normalization for total body surface area).

In dogs, testicular atrophy was noted after treatment with oral isotretinoin for approximately 30 weeks at dosages of 20 or 60 mg/kg/day (10 or 30 times the recommended clinical Zenatane dosage of 1 mg/kg/day, after normalization for total body surface area). In general, there was microscopic evidence for appreciable depression of spermatogenesis, but some sperm were observed in all testes examined, and in no instance were completely atrophic tubules seen.

📄 Package Label / Principal Display Panel 12 words ▾

Carton 10 mg:

Carton 20 mg:

Carton 30 mg:

Carton 40 mg:

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
10 capsules55111-0113-81 13,521 Rx · $1,922,690
Drug total (last 4 qtrs): 13,521 Rx · 685,620 units · $1,922,690 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Zenatane — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Zenatane. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$143.4K
Claims incl. refills
840
Beneficiaries
552
Spend / beneficiary
$259.70
Spend / claim
$170.66
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
🛡
This drug has a REMS — iPLEDGE REMS. A Risk Evaluation & Mitigation Strategy is an FDA-required safety program. It is available only through a restricted program (certified prescribers/pharmacies, enrollment, or required monitoring). See the boxed warning & full label below, and REMS@FDA ↗.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for ZENATANE (this brand).

Top reported reactions

Depression1,487
Adverse Drug Reaction1,307
Pregnancy1,042
Headache898
Dry Skin883
Arthralgia857
Abortion Induced819

Age at onset

Neonate62
Infant33
Child105
Adolescent1,814
Adult3,532
Elderly94

Reporter sex

23,441 reports
Male · 32%
Female · 67%
Unknown · 1%

Serious outcomes

Hospitalization1,493
Death464
Disabling383
Life-threatening316
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 3,052 467
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Dr. Reddy's Laboratories Limited. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 10 capsules (55111-0113-81). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Dr. Reddy's Laboratories Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.